Red One Medical and Prytime Medical Devices Announce Exclusive Partnership

Red One Medical, a proven government contractor providing best-in-class medical supplies to Veterans Affairs and the Department of Defense, is proud to exclusively partner with Prytime Medical Devices, Inc. (The REBOA Company™), a privately held medical technology company focused on minimally invasive solutions for trauma.

As a Service Disabled Veteran Owned Small Business (SDVOSB), Red One Medical specializes in serving the US military’s needs in Operational Medicine, Military Treatment Facilities and the VA.

Prytime Medical’s newly refined flagship product, the ER-REBOA™ PLUS Catheter, provides clinicians  an effective tool to control bleeding and stabilize patients in hemorrhagic shock, utilizing a minimally invasive technique called REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta). The catheter was designed specifically for emergency and critical care environments, making it a perfect match for combat medicine.

“Our flagship technology and technique arose from military medicine in the field, and now we’re bringing the lessons learned from war to civilian trauma back home,” said Prytime Medical’s CEO David Spencer. “Our partnership with veteran-owned Red One Medical supports our original mission to support combat wounded military members and those who treat them.”

“We’re proud to get these cutting-edge medical devices into the hands of US military trauma surgeons and other medical providers close to the point of injury,” said Red One Medical’s CEO Charles Pollak. “Red One works hard to bridge the gap between private sector innovations and government contracting, because we know these devices can save lives.”

The new PLUS design improves on the original ER-REBOA™ by adding five new features to help control massive non-compressible hemorrhage, including:
1) “Landing zone” markers to easily identify zones 1 and 3
2) Repackaged peel away sheath  to reduce prep time
3) Length markers on both sides of catheter for better visibility
4) Documentation tag to capture critical information
5) Guidewire compatible  for subsequent vascular procedures

Prytime Medical also offers the ER-REBOA™ PLUS Training Catheter and ARTI Simulator for arterial access training.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”